From Guidelines to Practice: Frontline Treatment Selection and Long-Term Management in ROS1-Positive Advanced NSCLC
EP. 1: RNA Sequencing and Tissue Strategies for ROS1 Detection
ByMatthew A. Gubens, MD, MS,Julia K. Rotow, MD,Estelamari Rodriguez, MD, MPH,Ana Velázquez Mañana, MD, MSc Julia K. Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A. Gubens, MD, MS, with panelists Estelamari Rodriguez, MD, MPH, and Ana I. Velázquez Mañana, MD, MSc.
EP. 2: Bridging Chemotherapy While Awaiting NGS Results
ByMatthew A. Gubens, MD, MS,Julia K. Rotow, MD,Estelamari Rodriguez, MD, MPH,Ana Velázquez Mañana, MD, MSc Estelamari Rodriguez, MD, MPH, explains why patients with advanced non-small cell lung cancer (NSCLC) and high programmed death ligand 1 (PD-L1) expression should not start immunotherapy while biomarker results are pending, since ROS1-positive disease responds poorly to it.
